Clinical Trial Results:
A Randomised, Double-blind Placebo-controlled Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of MIV-711 in Knee Joint Osteoarthritis
Summary
|
|
EudraCT number |
2015-003230-26 |
Trial protocol |
GB DE BG |
Global end of trial date |
23 May 2017
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
03 Jun 2018
|
First version publication date |
03 Jun 2018
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
MIV-711-201
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02705625 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Medivir AB
|
||
Sponsor organisation address |
Box 1086, Huddinge, Sweden, 14122
|
||
Public contact |
MIV-711 Clinical Study Information , Medivir AB, clinicaloperations@medivir.com
|
||
Scientific contact |
MIV-711 Clinical Study Information , Medivir AB, clinicaloperations@medivir.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
22 Sep 2017
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
23 May 2017
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
23 May 2017
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To assess the effect of MIV-711 on target knee average pain over 26 weeks as measured by an 11-point numerical rating scale (1 week recall) in patients with symptomatic and radiographic knee osteoarthritis
|
||
Protection of trial subjects |
Patients were observered in the clinics during the study visits.
During the whole treatment period, the following safety assessments were performed at each visit;
collection of adverse events and concomitant medications, vital signs, physical examination (full or targeted), ECG, standard safety laboratory parameters.
The last visit (at week 30) was a safety follow-up where all the above safety assessments were evaluated except physical examination.
In addition, a phone call was made after all dosing visits to assess safety and tolerability.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
28 Jan 2016
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Moldova, Republic of: 92
|
||
Country: Number of subjects enrolled |
Georgia: 34
|
||
Country: Number of subjects enrolled |
Romania: 8
|
||
Country: Number of subjects enrolled |
United Kingdom: 2
|
||
Country: Number of subjects enrolled |
Bulgaria: 38
|
||
Country: Number of subjects enrolled |
Germany: 70
|
||
Worldwide total number of subjects |
244
|
||
EEA total number of subjects |
118
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
162
|
||
From 65 to 84 years |
82
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Recruitment details |
Patients with chronic knee pain and Kellgren and Lawrence (K-L) classification Grade 2 or 3 were included in the study. The study was conducted in 6 study centres in 6 countries, Bulgaria, Georgia, Germany, Moldova, Romania and United Kingdom. | ||||||||||||||||||||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Screening details |
The study population was adults aged between 40 and 80 with symptomatic and radiographic knee Osteoarthritis. The patient's usual analgesic regimen (in case of use) must have remained the same for 4 weeks prior to the signature of the informed consent form. The study had a screening period of approximately 4 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Period 1 title |
Baseline
|
||||||||||||||||||||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst, Carer, Assessor | ||||||||||||||||||||||||||||||||||||||||||||||||
Blinding implementation details |
All IMPs were supplied in identical packaging and were similar in color, smell, taste and appearance.
|
||||||||||||||||||||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Baseline MIV-711 100 mg | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
MIV-711
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule, hard
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
The included excipients were microcrystalline cellulose, Starcap 1500, magnesium stearate and anhydrous colloidal silica.
|
||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Baseline MIV-711 200 mg | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
MIV-711
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule, hard
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
The included excipients were microcrystalline cellulose, Starcap 1500, magnesium stearate and anhydrous colloidal silica.
|
||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Baseline Placebo | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule, hard
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
For the placebo formulation, the excipient composition of the MIV-711 capsule was used, but the active substance was substituted with microcrystalline cellulose and Starcap 1500.
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Period 2
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Period 2 title |
Treatment
|
||||||||||||||||||||||||||||||||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst, Carer, Assessor | ||||||||||||||||||||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
MIV-711 100 mg | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
MIV-711 100 mg once daily for 26 weeks | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
MIV-711
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule, hard
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
The included excipients were microcrystalline cellulose, Starcap 1500, magnesium stearate and anhydrous colloidal silica.
|
||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
MIV-711 200 mg | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
MIV-711 200 mg once daily for 26 weeks | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
MIV-711
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule, hard
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
The included excipients were microcrystalline cellulose, Starcap 1500, magnesium stearate and anhydrous colloidal silica.
|
||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Placebo | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Placebo once daily for 26 weeks | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule, hard
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
For the placebo formulation, the excipient composition of the MIV-711 capsule was
used, but the active substance was substituted with microcrystalline cellulose and
Starcap 1500.
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Baseline MIV-711 100 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Baseline MIV-711 200 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Baseline Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Baseline MIV-711 100 mg
|
||
Reporting group description |
- | ||
Reporting group title |
Baseline MIV-711 200 mg
|
||
Reporting group description |
- | ||
Reporting group title |
Baseline Placebo
|
||
Reporting group description |
- | ||
Reporting group title |
MIV-711 100 mg
|
||
Reporting group description |
MIV-711 100 mg once daily for 26 weeks | ||
Reporting group title |
MIV-711 200 mg
|
||
Reporting group description |
MIV-711 200 mg once daily for 26 weeks | ||
Reporting group title |
Placebo
|
||
Reporting group description |
Placebo once daily for 26 weeks |
|
|||||||||||||||||
End point title |
NRS average target knee pain score at Week 26 | ||||||||||||||||
End point description |
Change from Visit 2 (Baseline) to Visit 8 (Week 26) in NRS average target knee pain score.
NRS (Numeric rating scale) ranges from 0 indicating -"no pain", to 10 indicating - "pain as bad as it could be".
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Week 26 compared to baseline
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Change in NRS average target knee pain score. | ||||||||||||||||
Statistical analysis description |
A linear mixed model based on the mITT population was used.
The model included fixed factors for treatment, time (measured in weeks), the interaction for treatment-by-time, baseline analgesic user (Yes/No), and random effect for clinical site. Baseline NRS was included as a covariate for adjustment.
An unstructured covariance matrix was used to model the covariance pattern in the mixed effects model.
|
||||||||||||||||
Comparison groups |
MIV-711 200 mg v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
141
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority [1] | ||||||||||||||||
P-value |
= 0.4055 [2] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||||||
Point estimate |
-0.0761
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-0.703 | ||||||||||||||||
upper limit |
0.55 | ||||||||||||||||
Notes [1] - For the primary endpoint, the Type I error for the tests of the two doses was protected by performing a fixed-sequence multiple-testing procedure in the following order: Step 1: 200 mg versus placebo Step 2: 100 mg versus placebo The second step was only considered as confirmatory provided the previous step was significant at a one-sided 5%-level (p<0.05). If the previous step was not significant, the analysis of the following step was considered descriptive. [2] - The p-values reported is from Step 1 (comparing 200 mg versus placebo). The corresponding p-value from Step 2 (comparing 100 mg versus placebo) was 0.1458. |
|
|||||||||||||||||
End point title |
MRI bone area of the target knee at Week 26 | ||||||||||||||||
End point description |
Change from Visit 2 (Baseline) to Visit 8 (Week 26) in MRI (Magnetic Resonance Imaging;) bone area of the target knee in mm^2.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 26 compared to baseline
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Change in knee joint MRI bone area | ||||||||||||||||
Statistical analysis description |
A linear mixed model based on the mITT population was used.
The model included fixed factors for treatment, time (measured in weeks), the interaction for treatment-by-time, baseline analgesic user (Yes/No), and random effect for clinical site. Baseline knee joint MRI bone area was included as a covariate for adjustment.
An unstructured covariance matrix was used to model the covariance pattern in the mixed effects model.
|
||||||||||||||||
Comparison groups |
MIV-711 200 mg v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
135
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority [3] | ||||||||||||||||
P-value |
= 0.0036 [4] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||||||
Point estimate |
-14.7
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-25.3 | ||||||||||||||||
upper limit |
-4.02 | ||||||||||||||||
Notes [3] - One model is fit for all comparison groups (MIV-711 200 mg, MIV-711 100 mg and placebo). This analysis reports the contrast that compares 200 mg versus placebo with respect to mean change from baseline in knee joint MRI bone area at Week 26. [4] - p-values reported are unadjusted p-values for tests of significance for the upper one-tailed alternative hypothesis Ha: bone area increase is lower in the active treatment arm compared to placebo. |
|||||||||||||||||
Statistical analysis title |
Change in knee joint MRI bone area | ||||||||||||||||
Statistical analysis description |
A linear mixed model based on the mITT population was used.
The model included fixed factors for treatment, time (measured in weeks), the interaction for treatment-by-time, baseline analgesic user (Yes/No), and random effect for clinical site. Baseline knee joint MRI bone area was included as a covariate for adjustment.
An unstructured covariance matrix was used to model the covariance pattern in the mixed effects model.
|
||||||||||||||||
Comparison groups |
MIV-711 100 mg v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
135
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority [5] | ||||||||||||||||
P-value |
= 0.0023 [6] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||||||
Point estimate |
-15.4
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-26 | ||||||||||||||||
upper limit |
-4.83 | ||||||||||||||||
Notes [5] - One model is fit for all comparison groups (MIV-711 200 mg, MIV-711 100 mg and placebo). This analysis reports the contrast that compares 100 mg versus placebo with respect to mean change from baseline in knee joint MRI bone area at Week 26. [6] - p-values reported are unadjusted p-values for tests of significance for the upper one-tailed alternative hypothesis Ha: bone area increase is lower in the active treatment arm compared to placebo. |
|
|||||||||||||||||
End point title |
CTX-I at Week 26 | ||||||||||||||||
End point description |
Biomarkers for bone resorption (serum CTX-I)
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 26 compared to baseline
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Change in CTX-I | ||||||||||||||||
Statistical analysis description |
A linear mixed model based on the mITT population was used.
The model included fixed factors for treatment, time (measured in weeks), the interaction for treatment-by-time, baseline analgesic user (Yes/No), and random effect for clinical site. Baseline CTX-I score was included as a covariate for adjustment.
An unstructured covariance matrix was used to model the covariance pattern in the mixed effects model.
|
||||||||||||||||
Comparison groups |
MIV-711 200 mg v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
140
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority [7] | ||||||||||||||||
P-value |
< 0.0001 [8] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||||||
Point estimate |
-0.254
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-0.302 | ||||||||||||||||
upper limit |
-0.206 | ||||||||||||||||
Notes [7] - One model is fit for all comparison groups (MIV-711 200 mg, MIV-711 100 mg and placebo). This analysis reports the contrast that compares 200 mg versus placebo with respect to mean change from baseline in CTX-I score at Week 26. [8] - p-values reported are unadjusted p-values for tests of significance for the upper one-tailed alternative hypothesis Ha: CTX-I score is lower in the active treatment arm compared to placebo. |
|||||||||||||||||
Statistical analysis title |
Change in CTX-I | ||||||||||||||||
Statistical analysis description |
A linear mixed model based on the mITT population was used.
The model included fixed factors for treatment, time (measured in weeks), the interaction for treatment-by-time, baseline analgesic user (Yes/No), and random effect for clinical site. Baseline CTX-I score was included as a covariate for adjustment.
An unstructured covariance matrix was used to model the covariance pattern in the mixed effects model.
|
||||||||||||||||
Comparison groups |
Placebo v MIV-711 100 mg
|
||||||||||||||||
Number of subjects included in analysis |
143
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority [9] | ||||||||||||||||
P-value |
< 0.0001 [10] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||||||
Point estimate |
-0.145
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-0.193 | ||||||||||||||||
upper limit |
-0.0983 | ||||||||||||||||
Notes [9] - One model is fit for all comparison groups (MIV-711 200 mg, MIV-711 100 mg and placebo). This analysis reports the contrast that compares 100 mg versus placebo with respect to mean change from baseline in CTX-I score at Week 26. [10] - p-values reported are unadjusted p-values for tests of significance for the upper one-tailed alternative hypothesis Ha: CTX-I score is lower in the active treatment arm compared to placebo. |
|
|||||||||||||||||
End point title |
CTX-II/Creatinine at Week 26 | ||||||||||||||||
End point description |
Cartilage degradation (urine CTX-II)
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 26 compared to baseline
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Change in CTX-II/Creatinine | ||||||||||||||||
Statistical analysis description |
A linear mixed model based on the mITT population was used.
The model included fixed factors for treatment, time (measured in weeks), the interaction for treatment-by-time, baseline analgesic user (Yes/No), and random effect for clinical site. Baseline CTX-II score was included as a covariate for adjustment.
An unstructured covariance matrix was used to model the covariance pattern in the mixed effects model.
|
||||||||||||||||
Comparison groups |
MIV-711 200 mg v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
140
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority [11] | ||||||||||||||||
P-value |
< 0.0001 [12] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||||||
Point estimate |
-270
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-339 | ||||||||||||||||
upper limit |
-201 | ||||||||||||||||
Notes [11] - One model is fit for all comparison groups (MIV-711 200 mg, MIV-711 100 mg and placebo). This analysis reports the contrast that compares 200 mg versus placebo with respect to mean change from baseline in CTX-II score at Week 26. [12] - p-values reported are unadjusted p-values for tests of significance for the upper one-tailed alternative hypothesis Ha: CTX-II score is lower in the active treatment arm compared to placebo. |
|||||||||||||||||
Statistical analysis title |
Change in CTX-II/Creatinine | ||||||||||||||||
Statistical analysis description |
A linear mixed model based on the mITT population was used.
The model included fixed factors for treatment, time (measured in weeks), the interaction for treatment-by-time, baseline analgesic user (Yes/No), and random effect for clinical site. Baseline CTX-II score was included as a covariate for adjustment.
An unstructured covariance matrix was used to model the covariance pattern in the mixed effects model.
|
||||||||||||||||
Comparison groups |
Placebo v MIV-711 100 mg
|
||||||||||||||||
Number of subjects included in analysis |
141
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority [13] | ||||||||||||||||
P-value |
< 0.0001 [14] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||||||
Point estimate |
-193
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-262 | ||||||||||||||||
upper limit |
-124 | ||||||||||||||||
Notes [13] - One model is fit for all comparison groups (MIV-711 200 mg, MIV-711 100 mg and placebo). This analysis reports the contrast that compares 100 mg versus placebo with respect to mean change from baseline in CTX-II score at Week 26. [14] - p-values reported are unadjusted p-values for tests of significance for the upper one-tailed alternative hypothesis Ha: CTX-II score is lower in the active treatment arm compared to placebo. |
|
|||||||||||||||||
End point title |
MRI of Cartilage Thickness (Femur) at Week 26 | ||||||||||||||||
End point description |
MRI of cartilage thickness in the Central Medial Femur Region of the target knee
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 26 compared to baseline
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Change in MRI of cartilage thickness (Femur) | ||||||||||||||||
Statistical analysis description |
A linear mixed model based on the mITT population was used.
The model included fixed factors for treatment, time (measured in weeks), the interaction for treatment-by-time, baseline analgesic user (Yes/No), and random effect for clinical site. Baseline MRI of cartilage thickness was included as a covariate for adjustment.
An unstructured covariance matrix was used to model the covariance pattern in the mixed effects model.
|
||||||||||||||||
Comparison groups |
MIV-711 200 mg v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
135
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority [15] | ||||||||||||||||
P-value |
= 0.1253 [16] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||||||
Point estimate |
0.0436
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-0.031 | ||||||||||||||||
upper limit |
0.118 | ||||||||||||||||
Notes [15] - One model is fit for all comparison groups (MIV-711 200 mg, MIV-711 100 mg and placebo). This analysis reports the contrast that compares 200 mg versus placebo with respect to mean change from baseline in MRI of cartilage thickness (Femur Region) at Week 26. [16] - p-values reported are unadjusted p-values for tests of significance for the upper one-tailed alternative hypothesis Ha: MRI of cartilage thinning (Femur Region) is lower in the active treatment arm compared to placebo. |
|||||||||||||||||
Statistical analysis title |
Change in MRI of cartilage thickness (Femur) | ||||||||||||||||
Statistical analysis description |
A linear mixed model based on the mITT population was used.
The model included fixed factors for treatment, time (measured in weeks), the interaction for treatment-by-time, baseline analgesic user (Yes/No), and random effect for clinical site. Baseline MRI of cartilage thickness was included as a covariate for adjustment.
An unstructured covariance matrix was used to model the covariance pattern in the mixed effects model.
|
||||||||||||||||
Comparison groups |
Placebo v MIV-711 100 mg
|
||||||||||||||||
Number of subjects included in analysis |
135
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority [17] | ||||||||||||||||
P-value |
= 0.0225 [18] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||||||
Point estimate |
0.0761
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
0.00173 | ||||||||||||||||
upper limit |
0.15 | ||||||||||||||||
Notes [17] - One model is fit for all comparison groups (MIV-711 200 mg, MIV-711 100 mg and placebo). This analysis reports the contrast that compares 100 mg versus placebo with respect to mean change from baseline in MRI of cartilage thickness (Femur Region) at Week 26. [18] - p-values reported are unadjusted p-values for tests of significance for the upper one-tailed alternative hypothesis Ha: MRI of cartilage thinning (Femur Region) is lower in the active treatment arm compared to placebo. |
|
|||||||||||||||||
End point title |
Normalised WOMAC, Pain Score | ||||||||||||||||
End point description |
|||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 26 compared to baseline
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Change in normalised WOMAC Pain score | ||||||||||||||||
Statistical analysis description |
A linear mixed model based on the mITT population was used.
The model included fixed factors for treatment, time (measured in weeks), the interaction for treatment-by-
time, baseline analgesic user (Yes/No), and random effect for clinical site. Baseline WOMAC Pain score was included as a covariate for adjustment.
An unstructured covariance matrix was used to model the covariance pattern in the mixed effects model.
|
||||||||||||||||
Comparison groups |
MIV-711 200 mg v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
141
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority [19] | ||||||||||||||||
P-value |
= 0.2887 [20] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||||||
Point estimate |
-1.77
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-8.02 | ||||||||||||||||
upper limit |
4.48 | ||||||||||||||||
Notes [19] - One model is fit for all comparison groups (MIV-711 200 mg, MIV-711 100 mg and placebo). This analysis reports the contrast that compares 200 mg versus placebo with respect to mean change from baseline in WOMAC Pain score at Week 26. [20] - p-values reported are unadjusted p-values for tests of significance for the lower one-tailed alternative hypothesis Ha: Reduction in WOMAC Pain score is higher in the active treatment arm compared to placebo. |
|||||||||||||||||
Statistical analysis title |
Change in normalised WOMAC Pain score | ||||||||||||||||
Statistical analysis description |
A linear mixed model based on the mITT population was used.
The model included fixed factors for treatment, time (measured in weeks), the interaction for treatment-by-
time, baseline analgesic (Yes/No) and random effect for clinical site. Baseline WOMAC Pain score was included as a covariate for adjustment.
An unstructured covariance matrix was used to model the covariance pattern in the mixed effects model.
|
||||||||||||||||
Comparison groups |
MIV-711 100 mg v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
143
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority [21] | ||||||||||||||||
P-value |
= 0.0753 [22] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||||||
Point estimate |
-4.55
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-10.8 | ||||||||||||||||
upper limit |
1.67 | ||||||||||||||||
Notes [21] - One model is fit for all comparison groups (MIV-711 200 mg, MIV-711 100 mg and placebo). This analysis reports the contrast that compares 100 mg versus placebo with respect to mean change from baseline in WOMAC Pain score at Week 26. [22] - p-values reported are unadjusted p-values for tests of significance for the lower one-tailed alternative hypothesis Ha: Reduction in WOMAC Pain score is higher in the active treatment arm compared to placebo. |
|
|||||||||||||||||
End point title |
Normalised WOMAC, Difficulty Score | ||||||||||||||||
End point description |
|||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 26 compared to baseline
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Change in normalised WOMAC Difficulty score | ||||||||||||||||
Statistical analysis description |
A linear mixed model based on the mITT population was used.
The model included fixed factors for treatment, time (measured in weeks), the interaction for treatment-by-time, baseline analgesic (Yes/No) and random effect for clinical site. Baseline WOMAC Difficulty score was included as a covariate for adjustment.
An unstructured covariance matrix was used to model the covariance pattern in the mixed effects model.
|
||||||||||||||||
Comparison groups |
MIV-711 200 mg v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
141
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority [23] | ||||||||||||||||
P-value |
= 0.2898 [24] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||||||
Point estimate |
-1.84
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-8.38 | ||||||||||||||||
upper limit |
4.7 | ||||||||||||||||
Notes [23] - One model is fit for all comparison groups (MIV-711 200 mg, MIV-711 100 mg and placebo). This analysis reports the contrast that compares 200 mg versus placebo with respect to mean change from baseline in WOMAC Difficulty score at Week 26. [24] - p-values reported are unadjusted p-values for tests of significance for the lower one-tailed alternative hypothesis Ha: Reduction in WOMAC Difficulty score is higher in the active treatment arm compared to placebo. |
|||||||||||||||||
Statistical analysis title |
Change in normalised WOMAC Difficulty score | ||||||||||||||||
Statistical analysis description |
A linear mixed model based on the mITT population was used.
The model included fixed factors for treatment, time (measured in weeks), the interaction for treatment-by-time, baseline analgesic (Yes/No) and random effect for clinical site. Baseline WOMAC Difficulty score was included as a covariate for adjustment.
An unstructured covariance matrix was used to model the covariance pattern in the mixed effects model.
|
||||||||||||||||
Comparison groups |
Placebo v MIV-711 100 mg
|
||||||||||||||||
Number of subjects included in analysis |
143
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority [25] | ||||||||||||||||
P-value |
= 0.1262 [26] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||||||
Point estimate |
-3.78
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-10.3 | ||||||||||||||||
upper limit |
2.72 | ||||||||||||||||
Notes [25] - One model is fit for all comparison groups (MIV-711 200 mg, MIV-711 100 mg and placebo). This analysis reports the contrast that compares 100 mg versus placebo with respect to mean change from baseline in WOMAC Difficulty score at Week 26. [26] - p-values reported are unadjusted p-values for tests of significance for the lower one-tailed alternative hypothesis Ha: Reduction in WOMAC Difficulty score is higher in the active treatment arm compared to placebo. |
|
|||||||||||||||||
End point title |
Normalised WOMAC, Stiffness Score | ||||||||||||||||
End point description |
|||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 26 compared to baseline
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Change in normalised WOMAC Stiffness score | ||||||||||||||||
Statistical analysis description |
A linear mixed model based on the mITT population was used.
The model included fixed factors for treatment, time (measured in weeks), the interaction for treatment-by-time, baseline analgesic (Yes/No) and random effect for clinical site. Baseline WOMAC Stiffness score was included as a covariate for adjustment.
An unstructured covariance matrix was used to model the covariance pattern in the mixed effects model.
|
||||||||||||||||
Comparison groups |
MIV-711 200 mg v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
141
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority [27] | ||||||||||||||||
P-value |
= 0.2 [28] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||||||
Point estimate |
-3.07
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-10.2 | ||||||||||||||||
upper limit |
4.1 | ||||||||||||||||
Notes [27] - One model is fit for all comparison groups (MIV-711 200 mg, MIV-711 100 mg and placebo). This analysis reports the contrast that compares 200 mg versus placebo with respect to mean change from baseline in WOMAC Stiffness score at Week 26. [28] - p-values reported are unadjusted p-values for tests of significance for the lower one-tailed alternative hypothesis Ha: Reduction in WOMAC Stiffness score is higher in the active treatment arm compared to placebo. |
|||||||||||||||||
Statistical analysis title |
Change in normalised WOMAC Stiffness score | ||||||||||||||||
Statistical analysis description |
A linear mixed model based on the mITT population was used.
The model included fixed factors for treatment, time (measured in weeks), the interaction for treatment-by-
time, baseline analgesic user (Yes/No), and random effect for clinical site. Baseline WOMAC Stiffness score was included as a covariate for adjustment.
An unstructured covariance matrix was used to model the covariance pattern in the mixed effects model.
|
||||||||||||||||
Comparison groups |
Placebo v MIV-711 100 mg
|
||||||||||||||||
Number of subjects included in analysis |
143
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority [29] | ||||||||||||||||
P-value |
= 0.0861 [30] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||||||
Point estimate |
-4.95
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-12.1 | ||||||||||||||||
upper limit |
2.17 | ||||||||||||||||
Notes [29] - One model is fit for all comparison groups (MIV-711 200 mg, MIV-711 100 mg and placebo). This analysis reports the contrast that compares 100 mg versus placebo with respect to mean change from baseline in WOMAC Stiffness score at Week 26. [30] - p-values reported are unadjusted p-values for tests of significance for the lower one-tailed alternative hypothesis Ha: Reduction in WOMAC Stiffness score is higher in the active treatment arm compared to placebo. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Adverse events were collected from baseline to safety follow-up visit
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
This study reports treatment-emergent AEs (TEAEs). A TEAE was defined as an AE that begins or that worsens in severity after at least one dose of IMP has been administered.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
18.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
MIV-711 100 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
MIV-711 200 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
13 Jan 2016 |
The purposes of this amendment were:
• to update the protocol with all revisions to date including amendments made at the request of country health authorities and to update patient and study-related spects such as assessments, objectives, and inclusion/exclusion criteria that were found necessary upon further internal review.
Minor typographic and grammar errors were corrected but are not detailed in this amendment summary, as they do not affect the conduct of the study. |
||
20 Jul 2016 |
The purposes of this amendment were:
• to include details about the option for all patients enrolled in the current study at the participating sites included in Extension Study MIV-711-202 to have the opportunity to participate in the extension protocol provided that they meet the eligibility criteria
• to confirm that females must be non-pregnant at study screening
• to delete the following: "At a patient's request, their data collected up to the point of withdrawal can also be withdrawn from the study and will not be used in the final analysis"
• to clarify which concomitant steroids can be used during the study
• to add a new subsection on Kellgren and Lawrence grade scoring
• to provide further detail on magnetic resonance imaging (MRI) procedures
• to provide clarity on visit numbers for Study MIV-711-201 and MIV-711-202
• to amend details of some of the footnotes in study schedule
• to provide further detail on the safety follow-up visit
• to provide an update on the planned analysis methods employed for the voluntarily consented pharmacogenomics samples
• to update the wording pertaining to the potential phototoxicity that could not be excluded at the start of study MIV-711-201 but that meanwhile has been discarded following cell based assays as outlined in the updated Investigator Brochure. Even though no signs of phototoxicity potential could be seen in the in vitro cell assay, it is desirable to maintain assay conditions all through the study, hence the suggested wording change
Minor typographic, formatting and grammar errors were corrected but are not detailed in this amendment summary, as they do not affect the conduct of the study or the safety of subjects.
|
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |